Breast Reconstruction
Conditions
Brief summary
This study compares outcomes of prospective mesh-based breast reconstructions to historical control breast reconstructions with no mesh.
Detailed description
Plastic surgeons have a variety of biologic and synthetic mesh available for use. However, no mesh has adequately evaluated safety and effectiveness for FDA approval or clearance for use in breast reconstruction. Therefore, no mesh is an appropriate comparator for a randomized clinical study. This multi-center, prospective, clinical study with matched historical controls of total submuscular 2-stage breast reconstructions with no mesh will evaluate the safety and effectiveness of DuraSorb® monofilament surgical mesh when implanted in subjects undergoing 2-stage breast reconstruction. Women scheduled for mastectomy and immediate 2-stage breast reconstruction will sign informed consent and satisfy eligibility criteria prior to the first stage of surgery and DuraSorb® implantation. Maximum study follow-up is through one year after definitive reconstruction.
Interventions
DEVICEDuraSorb®
Monofilament Surgical Mesh
Sponsors
Surgical Innovation Associates, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
22 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Female between the inclusive ages of 22 and 70 at the time of initial expander surgery * Scheduled to undergo either unilateral or bilateral mastectomy with immediate 2-stage breast reconstruction * Is able to understand the study requirements and is willing to provide written informed consent * Is willing and able to return for all scheduled study visits
Exclusion criteria
* Is pregnant or planning to become pregnant during study participation * Has a history of failed tissue expansion or breast implantation at the intended reconstruction site * has a residual gross tumor at the intended reconstruction site * has been treated for a systemic infection or a local infection at the surgical site that the investigator determines will affect the safety of the subject during breast reconstruction and/or mesh use * has, as determined by the investigator, unsuitable tissue integrity for immediate 2-stage breast reconstruction * has undergone previous radiation therapy to the reconstruction site or chest wall * is scheduled to undergo post-operative radiation therapy at the reconstruction site * has a Body Mass Index (BMI) \< 14 or \> 44 * has used nicotine products within 90 days of screening * is currently taking medications including non-NSAID anti-coagulants, immunosuppressants (including systemic steroids), or other medications determined by the investigator to place the subject at an increased risk of local complications of breast reconstruction * has been diagnosed with a comorbid condition determined by the investigator to place the subject at an increased risk of complications * has participated in any other clinical study that the investigator feels may interfere with this clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite Clinical Success (CCS) | 12 Month Follow-Up | This outcome measure is a combination of effectiveness and safety components. CCS is defined as intraoperative fill volume of at least 45% of the total expander size and the absence of expander or implant removal for cause or major cosmetic revision between the DuraSorb Treatment Arm and historical controls. |
| Local Complications of Breast Reconstruction | 12 Month Follow-Up | The rates of a set of breast reconstruction complications (i.e. infection, serum, necrosis, etc.) will be measured between the DuraSorb Treatment Arm and historical controls. |
Countries
United States
Outcome results
None listed